SCHEMBL4377797

SCHEMBL4377797

O=COC(=O)CCC(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.47
EGLN1 Q9GZT9 4/20 0.47
ALKBH5 Q6P6C2 1/20 0.47
SUCNR1 Q9BXA5 1/20 0.47
KDM5C P41229 3/20 0.44
PHF8 Q9UPP1 3/20 0.44
KDM2A Q9Y2K7 3/20 0.44
KDM6B O15054 2/20 0.44
SLC15A2 Q16348 1/20 0.38
MAPK1 P28482 1/20 0.38
SLC13A3 Q8WWT9 1/20 0.38
OR51E2 Q9H255 1/20 0.38
SLC22A6 Q4U2R8 1/20 0.36
TSHR P16473 4/20 0.36
NFKB1 P19838 1/20 0.35
PMP22 Q01453 1/20 0.35
KDM4E B2RXH2 2/20 0.35
FOLH1 Q04609 1/20 0.35
GABRR1 P24046 1/20 0.35
ABCC4 O15439 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28055752 0.97 LMNA (0.45) LMNAEGLN1ALKBH5SUCNR1KDM5C
Succinic Acid SCHEMBL15323172 0.91 EGLN1 (0.43) LMNAEGLN1ALKBH5SUCNR1KDM5C
Butane SCHEMBL7832973 0.91 FFAR3 (0.44) LMNAEGLN1ALKBH5SUCNR1KDM5C
SCHEMBL1436576 0.89 TSHR (0.40) LMNATSHR
SCHEMBL27917192 0.85 LMNA (0.52) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL5045326 0.85 TSHR (0.54) LMNAEGLN1ALKBH5SUCNR1SLC22A6
SCHEMBL27887441 0.83 TSHR (0.55) LMNAOR51E2SLC22A6TSHRNFKB1
SCHEMBL27928223 0.83 TSHR (0.55) LMNAOR51E2SLC22A6TSHRNFKB1
SCHEMBL1811252 0.83 TSHR (0.55) LMNAOR51E2SLC22A6TSHRNFKB1
SCHEMBL27732791 0.83 TSHR (0.55) LMNAOR51E2SLC22A6TSHRNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3436420-A1 METHOD FOR HYDROGENATING CARBOXYLIC ACIDS IN ORDER TO FORM ALCOHOLS BASF SE (DE) 2019-02-06 EP claimed
US-20230364183-A1 CARTILAGE-HOMING PEPTIDES FRED HUTCHINSON CANCER CENTER 2023-11-16 US disclosed
US-11802103-B2 Process of making calcium alpha-ketoglutarate PONCE DE LEON HEALTH DESIGNATED ACTIVITY COMPANY (IE) 2023-10-31 US disclosed
US-20230211000-A1 TISSUE-HOMING PEPTIDE CONJUGATES AND METHODS OF USE THEREOF Blaze Bioscience, Inc. 2023-07-06 US disclosed
US-11648290-B2 Cartilage-homing peptides FRED HUTCHINSON CANCER CENTER (US) 2023-05-16 US disclosed
US-11559580-B1 Tissue-homing peptide conjugates and methods of use thereof Blaze Bioscience, Inc. (US) 2023-01-24 US disclosed
US-11331393-B2 Renal-homing peptide conjugates and methods of use thereof Blaze Bioscience, Inc. (US) 2022-05-17 US disclosed
US-20220016202-A1 CARTILAGE-HOMING PEPTIDES FRED HUTCHINSON CANCER CENTER 2022-01-20 US disclosed
US-11090358-B2 Cartilage-homing peptides FRED HUTCHINSON CANCER RESEARCH CENTER (US) 2021-08-17 US disclosed
US-20210171589-A1 TRUNCATED CARTILAGE-HOMING PEPTIDES AND PEPTIDE COMPLEXES AND METHODS OF USE THEREOF Blaze Bioscience, Inc. 2021-06-10 US disclosed
EP-1228118-A1 POLYESTER ASSOCIATION THICKENERS Avecia Limited (GB) 2002-08-07 EP disclosed
WO-2001030882-A1 POLYESTER ASSOCIATION THICKENERS AVECIA LIMITED (GB) 2001-05-03 WO disclosed
US-6224893-B1 WOUND HEALING AGENT MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2001-05-01 US disclosed
EP-1011633-A1 SEMI-INTERPENETRATING OR INTERPENETRATING POLYMER NETWORKS FOR DRUG DELIVERY AND TISSUE ENGINEERING MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2000-06-28 EP disclosed
EP-0945721-A2 Biosensitive element for surface plasmon resonance measurements, and its method of manufacture DAI NIPPON PRINTING CO., LTD. (JP) 1999-09-29 EP disclosed
WO-1998052543-A1 SEMI-INTERPENETRATING OR INTERPENETRATING POLYMER NETWORKS FOR DRUG DELIVERY AND TISSUE ENGINEERING MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1998-11-26 WO disclosed
EP-0865439-A4 COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS ISIS PHARMACEUTICALS INC (US) 1998-11-11 EP disclosed
EP-0865439-A1 COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS ISIS PHARMACEUTICALS, INC. (US) 1998-09-23 EP disclosed
WO-1996040672-A1 COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS ISIS PHARMACEUTICALS, INC. (US) 1996-12-19 WO disclosed
US-3970598-A POLYESTER M & T CHEMICALS INC. (US) 1976-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11648290-B2 Cartilage-homing peptides CXCL12, CCL2, MATR3 LMNA 2378/4885EGLN1 3283/4885ALKBH5 4841/4885
US-20230364183-A1 CARTILAGE-HOMING PEPTIDES CXCL12, CCL2, MATR3 LMNA 2378/4885EGLN1 3283/4885ALKBH5 4841/4885
US-20220016202-A1 CARTILAGE-HOMING PEPTIDES CXCL12, CCL2, MATR3 LMNA 2378/4885EGLN1 3283/4885ALKBH5 4841/4885
US-20210171589-A1 TRUNCATED CARTILAGE-HOMING PEPTIDES AND PEPTIDE COMPLEXES AND METHODS OF USE THEREOF MATR3, CXCL12, UTRN LMNA 1769/4885EGLN1 3046/4885ALKBH5 4879/4885
US-11331393-B2 Renal-homing peptide conjugates and methods of use thereof CXCL12, ATP6V1B1, VIP LMNA 3674/4885EGLN1 3824/4885ALKBH5 4842/4885
US-20230211000-A1 TISSUE-HOMING PEPTIDE CONJUGATES AND METHODS OF USE THEREOF CXCL12, CCL2, CD44 LMNA 2866/4885EGLN1 3254/4885ALKBH5 4831/4885
US-11559580-B1 Tissue-homing peptide conjugates and methods of use thereof CXCL12, CCL2, CD44 LMNA 2866/4885EGLN1 3254/4885ALKBH5 4831/4885
US-11802103-B2 Process of making calcium alpha-ketoglutarate HOGA1, OGDH, GLS LMNA 2334/4885EGLN1 211/4885ALKBH5 1309/4885
US-11090358-B2 Cartilage-homing peptides CXCL12, CCL2, MATR3 LMNA 2378/4885EGLN1 3283/4885ALKBH5 4841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.